Patent classifications
A61L2400/04
MULTI-USE HEMOSTATIC COMPOSITION AND METHOD FOR PRODUCING SAME
The present invention relates to a multi-use hemostatic composition and a method for producing the same, and more particularly, to a technique relating to a multi-use a hemostatic agent in which a first component having a modified anionized substituent and a second component that is a polymer having adhesiveness are included to provide improved hemostatic ability and biocompatibility so as to have applicability into surgery, laparoscopy, and various surgical procedures.
TISSUE REPAIR SYSTEM
An implant for promoting accelerated wound healing. The implant comprises a non-flocculating fiber material, admixed with a settable fluid. The fiber component typically will have short fiber lengths, so as to avoid forming entangled masses or clumps when mixed with a fluid. In an embodiment, the fiber material is native collagen fibers and the settable fluid is an isolated blood fraction, such as platelet rich plasma and platelet poor plasma. The native collagen fiber retaining the native crosslinks of the source tissue and providing an architectural and structural scaffolding for advancing cellular infiltration. The wound healing implant will accelerate the bodies healing process, to provide better healing and less scar tissue of the wound site.
Coatings for implantable devices
Intraocular pressure sensors, systems, and methods of use. Implantable intraocular pressure sensing devices that are hermetically sealed and adapted to wirelessly communicate with an external device. The implantable devices can include a hermetically sealed housing, the hermetically sealed housing including therein: an antenna in electrical communication with a rechargeable power source, the rechargeable power source in electrical communication with an ASIC, and the ASIC in electrical communication with a pressure sensor.
MULTI-JUNCTIONAL BLEEDING SIMULATOR
Aspects of the present disclosure include a simulated wound apparatus allowing a wearer to simulate injuries for purposes of casualty simulation and medical response training. Aspects of the present disclosure are directed towards a wearable medical training device and more specifically a device for training of hemorrhage control procedures on junctional bleeding. The present disclosure, when used by a live actor, may allow users to safely simulate hemorrhaging in some of the most challenging blood vessels in the most challenging anatomical locations such as the carotid artery, the axillary artery, and the femoral artery. The present disclosure may further provide the ability for users to safely perform hemorrhage control procedures, such as compression and ligation. The simulated wound of the present disclosure may be compressed to control hemorrhage. The simulated wound receptacle of the present disclosure may be packed with hemostatic or simple gauze to control hemorrhage. The simulated blood vessel of the device may be ligated with hemostats or other ligating instruments or material and bandaged with pressure dressings to control hemorrhage.
SYSTEMS, DEVICES AND METHODS FOR DELIVERING SEALANTS TO TARGET TISSUE FOR CONTROLLING BLEEDING OF THE TARGET TISSUE
A sealant delivery device includes a housing, a matrix container connected with a distal end of the housing and being moveable between closed and opened positions, and a matrix, such as a hemostatic substrate, disposed within the matrix container. The sealant delivery device includes a sealant dispensing system in fluid communication with the matrix container that is configured for dispensing a sealant onto the matrix disposed within the matrix container. An actuator is coupled with the sealant dispensing system and the matrix container. The actuator is engageable for opening the matrix container for exposing the matrix and expressing the sealant onto the matrix. A component of the matrix container may be used to press the matrix and sealant expressed onto the matrix against target tissue to control bleeding of the target tissue.
HEMOSTATIC MATERIAL COMPOSITION
The hemostatic material composition contains a polysaccharide having a reactive group that reacts with a protein to form a crosslinking structure and contains a hydrophobic solvent.
HEMOSTATIC MATERIAL COMPOSITION
The hemostatic material composition contains a polysaccharide having a reactive group that reacts with a protein to form a crosslinking structure, a hydrophobic solvent, and a crosslinked particle containing one or more compounds selected from the group consisting of a crosslinked protein and a crosslinked polysaccharide.
FIBRINOGEN COMPRISING FORMULATION AND USES THEREOF
The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.
Polymeric compositions, delivery devices, and methods
Polymeric compositions, methods, and delivery devices for inhibiting bleeding are disclosed. The method includes applying a dried material topically to a wound site, where the material may include a cross-linked biologically compatible polymer which forms a hydrogel when exposed to blood and where the material may not include an active agent such as thrombin. A spring-loaded delivery device as described herein may be used to apply the dried material.
Hemostatic compositions
The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 17.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 17.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.